Get Your Own Businessabc AI Visibility ID
Boost AI visibility, credibility, and discoverability
Kamada was founded in 1990 by David Tzur, Ralph Hahn and Kamapharam Ltd., which was wholly owned by Kibbutz Beit Kama, until then Kamapharam was producing albumin, and its production facilities were acquired in full by Kamada In 1999, to a company owned by Hahn and another investor for $2.5 million. Hahn and Tzur headed the company by the beginning of 2013. The company completed its first public offering in 2005 on the Tel Aviv Stock Exchange.Today, the company specializes in the development, manufacture and marketing of proteins, especially for orphan diseases. The company produces about 10 injectable and marketed drugs in more than 15 countries around the world.Kamada is a member of the Biomed index on the Tel Aviv Stock Exchange, and as of December 2012, its shares were included in the Tel Aviv 100 index.In 2012, the company was ranked 456 among the 500 fastest growing companies in Europe according to the Deloitte Index, based on their income in 2007–2011.In May 2014, the company announced that it had not met the target set for the trial for a hereditary emphysema in inhalation. Following the failure of the experiment, the company's market value fell within a year from $500 million to $150 million.
